Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients

American Journal of Transplantation

Volumn 11, Issue 2, 2011, Pages 196-202

  Jordan, S C ^a   Toyoda, M ^a   Kahwaji, J ^a   Vo, A A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antibody mediated rejection (AMR); desensitization; donor specific antibody (DSA); immune deficiency; IVIG; kidney transplantation

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; RITUXIMAB; THYMOCYTE ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY MEDIATED REJECTION; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; BRONCHOSPASM; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; CYTOMEGALOVIRUS INFECTION; DESENSITIZATION; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEADACHE; HEART TRANSPLANTATION; HEMOLYTIC ANEMIA; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; PARVOVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ANEMIA, HEMOLYTIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; COMMON VARIABLE IMMUNODEFICIENCY; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOMODULATION; INFECTION; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; ORGAN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 79551499064     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03400.x     Document Type: Review

References (37)

1. Nimmerjahn F, Ravetch J,. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513-533.
2. Brandt D, Gershwin ME,. 2006. Common variable immune deficiency and autoimmunity. Autoimmun Rev 5: 465-470.
3. Jordan SC, Toyoda M, Vo A,. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009; 88: 1-6.
4. Durandy A, Kaveri S, Kuijpers T, et al,. Intravenous Immunoglobulians- Understanding Properties and Mechanisms. Clin Exp. Immunology 2009; 158: 2-13.
5. Jordan SC, Quartel AW, Czer LS, et al,. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800-805.
6. Casadei DH, del C, Rial M, Opelz G, et al,. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71: 53-58.
7. Jordan SC, Reinsmoen N, Peng A, et al,. Advances in diagnosis and managing antibody-mediated rejection. Pediatr Nephrol 2010; 25: 2035-2045.
8. Jordan SC, Tyan D, Stablein D, et al,. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly-HLA sensitized adult patients with end stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004: 15: 3256-3262.
9. United Network for Organ Sharing (UNOS) (unos.org). August 7, 2010.
10. Montgomery RA, Zachary AA, Racusen LC, et al,. Plasmapheresis and intravenous immune globulin pro- vides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
11. Shehata N, Palda V, Meyer R, et al,. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence -based practice guideline. Transf Med Rev 2010; 24: 7-27.
12. Nahirniak S, Hume H,. Guidelines for the use of immunoglobulin therapy for primary immune deficiency and solid organ transplantation. Transfus Med Rev 2010; 24: 1-6. 6.
13. Peraldi MN, Akposso K, Haymann JP, et al,. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation 1996; 62: 1670-1673.
14. Mai ML, Ahsan N, Wadei HM, et al,. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 2009; 88: 444.
15. Bachler K, Amico P, Honger G, et al,. Efficacy of induction therapy with ATG and intravenous immunoglobulin in patients with low-level donor specific HLA antibodies. Am J Transplant 2010; 10: 1254-1262.
16. Thielke JJ, West-Thielke PM, Herren HL, et al,. Living donor kidney transplantation across positive crossmatch: The university of illinois at chicago experience. Transplantation 2009; 87: 268-273.
17. Magee C, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S,. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: One center's experience. Transplantation 2008; 86: 96-103.
18. Vo A, Lukovsky M, Toyoda M, et al,. Rituximab and Intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251.
19. Vo A, Peng A, Toyoda M, et al,. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095-1102.
20. Loupy A, Suberbielle-Boissel C, Zuber J, et al,. Combined posttransplant prophylactic IVIg/anti-CD20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: A pilot study. Transplantation 2010; 89: 1403-1407.
21. Udl N, Shoenfeld Y,. Intravenous immunoglobulin-indications and mechanisms in cardiovascular disease. Autoimmun Rev 2008; 7: 445-452.
22. Pisani BA, Mullen GM, Malinowska K, et al,. Plasma- pheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999; 18: 701-706.
23. John R, Lietz K, Burke E, et al,. Intravenous immuno- globulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999; 100 (19 Suppl): II229-II235.
24. Appel III JZ, Hartwig MG, Davis RD, Reinsmoen NL,. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Hum Immunol 2005; 66: 378-386.
25. Hachem R, Yusen R, Meyers B, et al,. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 2010; 29: 973-980.
26. Lefaucher G, Nochy D, Andrade J, et al,. Comparison of combination plasmapheresis/IVIG/Anti-CD20 versus high dose IVIG in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099-1107.
27. Â in Highly-HLA Sensitized Patients (HS) transplanted after desensitization With IVIG+Rituximab. Am J Transplantation 2010; 10: 317.
28. Kaposztas Z, Podder H, Mauiyyedi S, et al,. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23: 63-73.
29. Kessler L, Parissiadis A, Bayle F, et al,. Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy. Am J Transplant 2009; 9: 1961-1966.
30. Manhorter S, Yamani M,. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13: 581-585.
31. Smith J, Jordan SC,. IVIG As treatment for BK virus nephropathy. Pediatr Transplant 2008; 13: 11-13.
32. Rhada R, Jordan SC, Puliyanda D, et al,. Cellular immune response to CMV in renal transplant recipients. Am J Transplant 2005; 5: 110-117.
33. Shen Q, Xu H, Cao Q, et al,. Long-term remission of recurrent parvovirus B19 infection in a pediatric renal transplant recipient. Pediatr Transplant 2010; Epub ahead of print.
34. Barsoum N, Bannapradist S, Moudgil A, Toyoda M, Vo A, Jordan SD,. Treatment of parvovirus B-19 infection allows for successful kidney transplantation without disease recurrence. Am J Transplant 2002; 2: 425-428.
35. Potena L, Holweg CT, Chin C, et al,. Acute rejection and cardiac allograft vascular disease reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006; 82: 398-405.
36. Vo AA, Cam V, Toyoda M, et al,. Safety and adverse events profiles of IVIG products used for immunomodulation: A single-center experience. Clin J Am Soc Nephrol 2006; 4: 844-852.
37. Kahwaji J, Baker E, Pepkowitz S, et al,. Acute hemolysis after high dose IVIG therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009; 24: 155-160.